Medico Remedies Ltd

Medico Remedies Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.15, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.72, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company's return on equity (ROE) is 5.92%, and its return on assets (ROA) is 3.22%. These figures are below the industry median for ROE and ROA, which are typically higher in the pharmaceutical sector due to the high margins associated with drug development and sales. The company's operating margin is 9.46%, and its net profit margin is 7.50%, both of which are in line with the industry average.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data suggests a need for further transparency in the company's reporting.

Looking ahead, the company's revenue is projected to grow by 4.5% in the current fiscal year and by 3.2% in the next fiscal year. These growth rates are modest compared to the industry average, which is driven by innovation and new product launches. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which may affect its long-term growth potential.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key liquidity flag. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. However, the company's reliance on operating cash flow to fund its operations may become a concern if cash flow from operations declines.

Recent filings and transcripts do not indicate any major strategic shifts or significant events that would impact the company's operations or financial performance. The company's 10-K filing highlights ongoing research and development activities, but there are no disclosures of major product launches or regulatory approvals in the near term. The absence of recent significant events suggests a stable but potentially stagnant business environment.

Net income surged 40.5% CAGR over four years, significantly outpacing the 5.4% revenue growth rate.

Debt-to-equity ratio of 0.15 is lower than the cohort median of 0.18, suggesting a conservative capital structure.

Free cash flow turned negative at minus 127 million INR in FY0, reversing previous positive generation trends.

Cash conversion ratio of 0.79 trails the pharmaceutical cohort median of 0.95, indicating weaker cash generation efficiency.

Long-term debt increased to 147 million INR in FY0, rising from 81 million INR in FY-1.

The company faces medium liquidity risk and medium credit risk according to current risk flag assessments.

Revenue growth slowed to 4.2% year-over-year in FY0, down from higher historical expansion rates.